Baraliakos X, et al. Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial. ACR 2018, abstract L13.
Promotie: Factoren die de respons op TNF-remmers beïnvloeden
jun 2021 | Arthritis psoriatica, RA